Sabtu, 27 Desember 2014

Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatmen

Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic

Discover the trick to enhance the lifestyle by reading this Modulators Of Glutamatergic Signaling As Potential Treatments For Neuropsychiatric Disorders (Psychiatry - Theory, Applications And Treatments), By Zoran M., M.d. Pavlovic This is a kind of publication that you need currently. Besides, it can be your favorite publication to read after having this book Modulators Of Glutamatergic Signaling As Potential Treatments For Neuropsychiatric Disorders (Psychiatry - Theory, Applications And Treatments), By Zoran M., M.d. Pavlovic Do you ask why? Well, Modulators Of Glutamatergic Signaling As Potential Treatments For Neuropsychiatric Disorders (Psychiatry - Theory, Applications And Treatments), By Zoran M., M.d. Pavlovic is a book that has various unique with others. You may not should know that the author is, how widely known the job is. As sensible word, never ever judge the words from which talks, but make the words as your good value to your life.

Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic

Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic



Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic

Best PDF Ebook Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic

Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic

  • Published on: 2015-10-10
  • Original language: English
  • Dimensions: 10.50" h x 7.25" w x .50" l,
  • Binding: Hardcover
  • 184 pages
Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic


Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic

Where to Download Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic

Most helpful customer reviews

0 of 0 people found the following review helpful. Some areas like depression, multiple sclerosis By Amazon Customer Endorsement of ''Modulators of Glutamatergic Signaling as Potential Treatments of Neuropsychiatric Disorders,'' edited by Zoran Pavlovic, M.D.Glutamate is the single most common excitatory neurotransmitter in the human CNS and profoundly impacts on a number of brain circuits implicated in the production of mental disorders. For example, in schizophrenia it is hypothesized that there is hypofunctioning of the ionotropic N-methyl-d-aspartate (NMDA) glutamate receptor, which in turn results in excessive dopamine release in the striatum, leading to positive symptoms such as hallucinations and delusions, and inadequate dopamine release in the frontal cortex, leading to cognitive dysfunction, negative symptoms, and disturbances in mood. Thus alterations in glutamatergic signaling are at the core of these symptoms, and in addition to NMDA hypofunction, disturbances in feedback loops are also present. Dr. Pavlovic’s book provides an overview on these and other clinically relevant issues that will help readers think through their practical and research implications for treatment and drug development. Particularly compelling are chapters that cover a myriad of common and important disease states, including attention-deficit hyperactivity disorder, obsessive-compulsive disorder, Alzheimer’s disease, migraine headache, addictive disorders, and clinical concerns that are encountered across different disorders such as aggression.Leslie Citrome, MD, MPHClinical Professor of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY USAEditor in Chief, International Journal of Clinical Practice, Wiley-Blackwell, Oxford, UKJuly 22, 2015"It is clear that the glutamatergic system plays a critical role in modulating brain circuits that regulate core symptom domains across a range of neuropsychiatric conditions. As such, experimental therapeutic approaches to glutamate signalling have assumed increasing importance in academic and industry approaches to CNS drug development, and this book is a invaluable resource to guide such development in our field."Eric Hollander, MDDirector - Autism and Obsessive Compulsive Spectrum Program,and Anxiety and Depression Program,Clinical Professor of Psychiatry and Behavioral Sciences,Albert Einstein College of Medicine andMontefiore Medical CenterA large body of both preclinical and clinical data points to the important role of the glutamate system in neuropsychiatric disorders. This volume represents a timely assessment of the involvement of the glutamate system in a range of psychiatric disorders and the therapeutic potential of agents targeting this system.John Dunlop Vice President and Head, Neuroscience Innovative Medicines at AstraZenecaThere are many unmet needs in the treatment of psychiatric illnesses including major depression, bipolar disorders, anxiety disorders, schizophrenia, substance abuse, ADHD, and dementia, among others. The new Research Domain Criteria (RDoc) initiative from the NIMH has challenged the validity of our current diagnostic systems and aims to link symptom domains to biomarkers to improve treatment outcomes.Strategies to identify innovative drug targets to meet the unmet needs in the treatment of psychiatric illnesses continue. Glutamate, the primary excitatory neurotransmitter in the human brain, has been implicated in several psychiatric illnesses and remains a “hot” target for drug discovery. Even though glutamate can be modulated at several different levels, current drugs in development target it at only a few levels. Understanding the role of glutamate in attention, anxiety, mood, psychotic, cognitive and substance use disorders is challenging for the trainee as well as for the researchers and practicing clinicians.Under the masterful editorship of Zoran Pavlovic, M.D., the authors of “Modulators of Glutamatergic Signaling as Potential Treatments for Neuropsychiatric Disorders” have made an important contribution to the field. The authors provide a lucid, scholarly and compelling story on glutamate, which will be of interest not just to medical students, residents, and fellows, but also to academic researchers and the practicing clinician.Prakash Masand MDChairman and CEOGlobal Medical EducationThe book “Modulators of glutamatergic signaling as potential treatments of neuropsychiatric disorders” edited by Zoran Pavlovic and published by Nova Science comes at a critical moment when drug development for psychiatric and neurological disorders is searching for new targets. Glutamate is widely present in the brain and is involved in normal nervous system functioning and neuroprotection. Over the past years the glutamatergic system has received increased attention due to its role in the pathology of several conditions related to cognition, mood, and neurodegeneration. Currently, an important number of compounds are in clinical development targeting the various receptors and transporters that play a part in glutamatergic signaling.Experts from academia and the pharmaceutical industry have contributed chapters on ADHD, Alzheimer’s, migraine, aggression, schizophrenia, OCD and addiction, each containing a description of the disorder and providing the historical perspective in relation to glutamate. Current treatments targeting the glutamate system and future perspectives for new compounds are discussed for the various indications. The book provides a solid and succinct overview to a broad audience and will be of interest to students of medicine or pharmacology, clinical pharmacologists, psychiatrists and neurologists concerned with pharmacotherapy and drug developers in the pharmaceutical industry involved with CNS compounds.Some areas like depression, multiple sclerosis, ALS, epilepsy, stroke or traumatic brain injury where glutamate may also be important, are not covered but could become the topic of a second volume or be included in a future edition. Raimund Buller MDVice President, Global Clinical Research PsychiatryLundbeckThis book opens a new chapter in neuropsychopharmacology. It provides with a comprehensive review of the glutamatergic system and its involvement in multiple disorders of the central nervous system.For more than five decades, the focus on monoamines transmitters helped the development of multiple therapies for neurological and psychiatric disorders. The glutamatergic system is much more complex and has the potential to offer novel approches to help patients. A plethora of evidence, in preclinical and clinical research, support the involvement of glutamate in most disorders of the central nervous system.Multiple research studies have been conducted to evaluate the effect of different drugs and new molecular entities on various psychiatric disorders. Existing therapies with an effect on the glutamatergic system showed some promising results indicating their potential benefit on different symptom domains such as apathy, avolition and anhedonia. However, more recent research posed additional challenges. A “soft” enhancement of glutamatergic transmissionthrough the blockade of glycine transporters did not lead to a consistent therapeutic benefit in schizophrenia, substance abuse and OCD. However, some beneficial effects were observed on specific symptom domains such as motivation. Modulators of mGLU-R5 receptors showed a beneficial effect in patients with major depressive disorders with inadequate response to SSRIs and SNRIs. If these effects are confirmed, research focused on symptom domains rather than diagnoses will help adequately evaluate the potential benefit of novel therapies involving the glutamatergic system.George Garibaldi MDVP CNS DevelopmentF. Hoffmann-La Roche

See all 1 customer reviews... Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic


Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic PDF
Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic iBooks
Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic ePub
Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic rtf
Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic AZW
Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic Kindle

Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic

Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic

Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic
Modulators of Glutamatergic Signaling As Potential Treatments for Neuropsychiatric Disorders (Psychiatry - Theory, Applications and Treatments), by Zoran M., M.d. Pavlovic

Tidak ada komentar:

Posting Komentar